Efficacy of newly developed food for special dietary use in the diet of patients with non-alcoholic steatohepatitis

Abstract

Although diet plays a leading role in treatment of non-alcoholic fatty disease (and, in particular, non-alcoholic steatohepatitis), specialized foods for the treatment of these patients have not yet been developed.

The aim of the study was to assess efficacy of the food for special dietary use (FSDU) in patients with non-alcoholic steatohepatitis.

Material and methods. New FSDU contained (% of the RDAs): protein – 8%; fat – 7% (including ω-3 PUFA – 40%); soluble dietary fiber – 180%; phospholipids – 25%; alpha-lipoic acid – 33%; betaine – 10%; 12 mineral substances – 13–44%; 13 vitamins – 24–140%. The study (NCT04308980) was approved by local ethics committee and enrolled patients with diagnosis of NASH. Subjects were randomized to the following groups: those received iso-calorie diet (according to resting energy expenditures, by indirect calorimetry) alone (ICD) and iso-calorie diet + FSDU (2 portions per day, 14 days) (ICD + FSDU group). Safety was assessed based on clinical and laboratory data. Repeated measurements (baseline vs those on the 15th day of the study) of body composition assessed by bioelectrical impedance analysis, and blood chemistry were compared.

Results. The results of complex examination of 20 subjects (12 in ICD + FSDU and 8 in ICD group) served as a source for the study. Initially, groups did not differ by age, sex, and body mass index (BMI). The product was well tolerated. In contrast to ICD group, those in ICD + FSDU group demonstrated greater decrease of weight: BMI initially (BMI0) (M±σ): 38.7±5.4 kg/m2 vs BMI at the end-point (BMIEOT) 36.7±5.1 kg/m2, p=0.003 in ICD + FSDU group, whereas in the ICD group BMI0=38.9±7.2 vs BMIEOT=38.9±7.3 kg/m2, p=0.08. These results were reached predominantly by a decrease of fat mass: body fat weight (BFW0) 50.2±10.7 vs BFWEOT=48.5±10.8 kg, p=0.002 in ICD + FSDU group, whereas BFW0=48.9±11.4 vs BFWEOT=47.8±11.6 kg, p=0.07 in ICD group. The activity of alanine and aspartate aminotransferase, gamma-glutamil transpeptidase and alkaline phosphatase decreased in ICD + FSDU group (р≤0.05), whereas in ICD group the difference between initial and control assessment was not significant (р≤0.10).

Conclusion. The new FSDU is well tolerated by patients with NASH. In combination with iso-calorie diet, it may increase efficacy of weight loss, predominantly by fat.

Keywords:non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; specialized food; food for special dietary uses; diet

Funding. This study had financial support by the Ministry of Science and Higher Education of Russian Federation (research project No. 0529-2019-0055).

Conflict of interest. The authors declare no conflict of interest.

For citation: Sasunova A.N., Morozov S.V., Sobolev R.V., Isakov V.A., Kochetkova A.A., Vorobyeva I.S. Efficacy of newly developed food for special dietary use in the diet of patients with non-alcoholic steatohepatitis. Voprosy pitaniia [Problems of Nutrition]. 2022; 91 (2): 31–42. DOI: https://doi.org/10.33029/0042-8833-2022-91-2-31-42 (in Russian)

References

1. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64 (6): 1388–402. DOI: https://doi.org/10.1016/j.jhep.2015.11.004 ; PMID: 27062661.

2. Carr R.M., Oranu A., Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016; 45 (4): 639–52. DOI: https://doi.org/10.1016/j.gtc.2016.07.003 PMID: 27837778; PMCID: PMC5127277.

3. Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012; 32 (1): 3–13. DOI: https://doi.org/10.1055/s-0032-1306421 ; PMID: 22418883.

4. Bedossa P.; FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014; 60 (2): 565–75. DOI: https://doi.org/10.1002/hep.27173 ; PMID: 24753132.

5. Lazebnik L.B., Golovanova E.V., Turkina S.V., Raykhel’son K.L., Okovitiy S.V., Drapkina O.M., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2021; 185 (1): 4–52. DOI: https://doi.org/10.31146/1682-8658-ecg-185-1-4-52 (in Russian)

6. McPherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015; 62 (5): 1148–55. DOI: https://doi.org/10.1016/j.jhep.2014.11.034 ; PMID: 25477264.

7. Pais R., Charlotte F., Fedchuk L., Bedossa P., Lebray P., Poynard T., et al.; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013; 59 (3): 550–6. DOI: https://doi.org/10.1016/j.jhep.2013.04.027 ; PMID: 23665288.

8. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78.e5. DOI: https://doi.org/10.1053/j.gastro.2015.04.005 ; PMID: 25865049.

9. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51 (1): 121–9. DOI: https://doi.org/10.1002/hep.23276 ; PMID: 19827166; PMCID: PMC2799538.

10. Chiu S., Sievenpiper J.L., de Souza R.J., Cozma A.I., Mirrahimi A., Carleton A.J., et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr. 2014; 68 (4): 416–23. DOI: https://doi.org/10.1038/ejcn.2014.8 ; PMID: 24569542; PMCID: PMC3975811.

11. Barrera F., George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014; 18 (1): 91–112. DOI: https://doi.org/10.1016/j.cld.2013.09.009 ; PMID: 24274867.

12. Gerber L., Otgonsuren M., Mishra A., Escheik C., Birerdinc A., Stepanova M., et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012; 36 (8): 772–81. DOI: https://doi.org/10.1111/apt.12038 ; PMID: 22958053.

13. Eslamparast T., Tandon P., Raman M. Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. Nutrients. 2017; 9 (8): 800. DOI: https://doi.org/10.3390/nu9080800

14. Zhao H., Yang A., Mao L., Quan Y., Cui J., Sun Y. Association between dietary fiber intake and non-alcoholic fatty liver disease in adults. Front Nutr. 2020; 7: 593735. DOI: https://doi.org/10.3389/fnut.2020.593735

15. Rahmanabadi A., Mahboob S., Amirkhizi F., Hosseinpour-Arjmand S., Ebrahimi-Mameghani M. Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Food Funct. 2019; 10 (8): 4941–52. DOI: https://doi.org/10.1039/c9fo00449a

16. Hosseinpour-Arjmand S., Amirkhizi F., Ebrahimi-Mameghani M. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2019; 44 (2): 258–67. DOI: https://doi.org/10.1111/jcpt.12784

17. Cerletti C., Colucci M., Storto M., Semeraro F., Ammollo C.T., Incampo F., et al. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. Br J Nutr. 2020; 123 (2): 190–7. DOI: https://doi.org/10.1017/S0007114519002484

18. Saleh D.O., Ahmed R.F., Amin M.M. Modulatory role of Co-enzyme Q10 on methionine and choline deficient diet-induced non-alcoholic steatohepatitis (NASH) in albino rats. Appl Physiol Nutr Metab. 2017; 42 (3): 243–9. DOI: https://doi.org/10.1139/apnm-2016-0320

19. Chen K., Chen X., Xue H., Zhang P., Fang W., Chen X., et al. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. Food Funct. 2019; 10 (2): 814–23. DOI: https://doi.org/10.1039/c8fo01236a

20. Vorob’yova V.M., Vorob’yova I.S., Morozov S.V., Sasunova A.N., Kochetkova A.A., Isakov V.A. Specialized products for dietary correction of the diet of patients with non-alcoholic steatohepatitis. Voprosy pitaniia [Problems of Nutrition]. 2021; 90 (2): 100–9. DOI: https://doi.org/10.33029/0042-8833-2021-90-2-100-109 (in Russian)

21. Popova A.Yu., Tutelyan V.A., Nikityuk D.B. On the new (2021) Norms of physiological requirements in energy and nutrients of various groups of the population of the Russian Federation. Voprosy pitaniia [Problems of Nutrition]. 2021; 90 (4): 6–19. DOI: https://doi.org/10.33029/0042-8833-2021-90-4-6-19 (in Russian)

22. Selezneva K.S., Isakov V.A., Sentsova T.B., Kirillova O.O. Isomeric specific analysis of hydroxyeicosatetraenoic acid in blood samples from obese patients with non-alcoholic and alcoholic steatohepatitis. Voprosy pitaniia [Problems of nutrition]. 2014; 83 (5): 73-8. (in Russian)

23. Topilskaya N.V., Selezneva K.S., Nefedova E.A., Isakov V.A. Diet therapy for non-adipose fatty liver disease with the inclusion of a low-fat product. Russkiy meditsinskiy zhurnal. Gastroenterologiya [Russian Medical Journal. Gastroenterology]. 2012; (35): 1702–4. (in Russian)

24. Namazi N., Larijani B., Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2018; 37 (2): 419–28. DOI: https://doi.org/10.1016/j.clnu.2017.06.002

25. Cerletti C., Colucci M., Storto M., Semeraro F., Ammollo C.T., Incampo F., et al. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. Br J Nutr. 2020; 123 (2): 190–7. DOI: https://doi.org/10.1017/S0007114519002484

26. Masharova A.A., Danilevskaya N.N. Non-alcoholic steatohepatitis: from pathogenesis to therapy. Russkiy meditsinskiy zhurnal. Gastroenterologiya [Russian Medical Journal. Gastroenterology]. 2013; (31): 1642–5. (in Russian)

27. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362 (18): 1675–85. DOI: https://doi.org/10.1056/NEJMoa0907929 ; PMID: 20427778; PMCID: PMC2928471.

28. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007; 297 (8): 842–57. DOI: https://doi.org/10.1001/jama.297.8.842 Erratum in: JAMA. 2008; 299 (7): 765–6. PMID: 17327526.

29. Schürks M., Glynn R.J., Rist P.M., Tzourio C., Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010; 341: c5702. DOI: https://doi.org/10.1136/bmj.c5702 PMID: 21051774; PMCID: PMC2974412.

30. Klein E.A., Thompson I.M. Jr, Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306 (14): 1549–56. DOI: https://doi.org/10.1001/jama.2011.1437

31. Koopman N., Molinaro A., Nieuwdorp M., Holleboom A.G. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019; 50 (6): 628–39. DOI: https://doi.org/10.1111/apt.15416 Epub 2019 Aug 2. Erratum in: Aliment Pharmacol Ther. 2019; 50 (10): 1142. PMID: 31373710.

32. Safari Z., Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 2019; 76 (8): 1541–58. DOI: https://doi.org/10.1007/s00018-019-03011-w

33. Philips C.A., Augustine P., Yerol P.K., Ramesh G.N., Ahamed R., Rajesh S., et al. Modulating the intestinal microbiota: therapeutic opportunities in liver disease. J Clin Transl Hepatol. 2020; 8 (1): 87–99. DOI: https://doi.org/10.14218/JCTH.2019.00035

34. Wijarnpreecha K., Lou S., Watthanasuntorn K., Kroner P.T., Cheungpasitporn W., Lukens F.J., et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020; 32 (5): 601–8. DOI: https://doi.org/10.1097/MEG.0000000000001541

35. Sanders M.E., Merenstein D.J., Reid G., Gibson G.R., Rastall R.A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019; 16 (10): 605–16. DOI: https://doi.org/10.1038/s41575-019-0173-3 ; Epub 2019 Jul 11. Erratum in: Nat Rev Gastroenterol Hepatol. 2019; Aug 9. PMID: 31296969.

36. Loman B.R., Hernández-Saavedra D., An R., Rector R.S. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev. 2018; 76 (11): 822–39. DOI: https://doi.org/10.1093/nutrit/nuy031

37. Pang J., Xu W., Zhang X., Wong G.L., Chan A.W., Chan H.Y., et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 46 (2): 175–82. DOI: https://doi.org/10.1111/apt.14119

38. Kurtanov K.A., Sydykova L.A., Pavlova N.I., Filippova N.P., Dodokhov V.V., Aspolikhova G.A., et al. Polymorphism of the adiponutrin gene (PNPLA3) in the indigenous inhabitants of the Republic of Sakha (Yakutia) with type 2 diabetes mellitus. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2018; 46 (3): 258–63. DOI: https://doi.org/10.18786/2072-0505-018-46-3-258-263 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

SCImago Journal & Country Rank
Scopus CiteScore
CHIEF EDITOR
CHIEF EDITOR
Viktor A. Tutelyan
Full Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Scientific Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety (Moscow, Russia)

Journals of «GEOTAR-Media»